GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genematrix Inc (XKRX:109820) » Definitions » Cyclically Adjusted Revenue per Share

Genematrix (XKRX:109820) Cyclically Adjusted Revenue per Share : ₩572.21 (As of Mar. 2025)


View and export this data going back to 2009. Start your Free Trial

What is Genematrix Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Genematrix's adjusted revenue per share for the three months ended in Mar. 2025 was ₩123.805. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₩572.21 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Genematrix's average Cyclically Adjusted Revenue Growth Rate was 0.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 3.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Genematrix was 7.30% per year. The lowest was 0.60% per year. And the median was 3.35% per year.

As of today (2025-05-31), Genematrix's current stock price is ₩2945.00. Genematrix's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₩572.21. Genematrix's Cyclically Adjusted PS Ratio of today is 5.15.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genematrix was 57.13. The lowest was 4.06. And the median was 8.18.


Genematrix Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Genematrix's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genematrix Cyclically Adjusted Revenue per Share Chart

Genematrix Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 553.58 539.64 551.81 563.26 565.75

Genematrix Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 571.26 568.42 566.27 565.75 572.21

Competitive Comparison of Genematrix's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, Genematrix's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genematrix's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genematrix's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genematrix's Cyclically Adjusted PS Ratio falls into.


;
;

Genematrix Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genematrix's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=123.805/122.5900*122.5900
=123.805

Current CPI (Mar. 2025) = 122.5900.

Genematrix Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 104.330 100.051 127.833
201509 102.787 100.111 125.867
201512 111.994 100.220 136.992
201603 106.476 100.561 129.801
201606 95.326 100.791 115.943
201609 88.985 101.461 107.516
201612 83.895 101.561 101.266
201703 75.657 102.851 90.177
201706 57.253 102.611 68.400
201709 58.570 103.491 69.379
201712 87.025 102.991 103.586
201803 72.812 104.101 85.744
201806 53.370 104.130 62.831
201809 78.043 105.651 90.556
201812 75.614 104.351 88.830
201903 72.016 104.491 84.490
201906 71.804 104.881 83.928
201909 61.932 105.200 72.169
201912 84.214 105.121 98.208
202003 104.578 105.354 121.687
202006 316.012 105.112 368.559
202009 651.125 106.198 751.631
202012 183.506 105.765 212.697
202103 180.293 107.357 205.875
202106 103.896 107.579 118.394
202109 128.956 108.759 145.355
202112 181.471 109.676 202.838
202203 243.838 111.848 267.256
202206 118.544 114.072 127.396
202209 86.594 114.715 92.538
202212 113.636 115.179 120.948
202303 113.143 116.507 119.050
202306 112.317 117.182 117.500
202309 123.653 118.964 127.422
202312 149.286 118.837 154.000
202403 90.849 120.123 92.715
202406 147.188 120.007 150.356
202409 122.472 120.861 124.224
202412 132.716 121.135 134.310
202503 123.805 122.590 123.805

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Genematrix  (XKRX:109820) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Genematrix's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2945.00/572.21
=5.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genematrix was 57.13. The lowest was 4.06. And the median was 8.18.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Genematrix Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Genematrix's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Genematrix Business Description

Traded in Other Exchanges
N/A
Address
700, Daewangpangyo-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 463-400
Genematrix Inc is a biotech company engaged in the development of the platform and molecular diagnostics products. Its products include NeoPlexTM STI-7 Detection kit, OmniPlex-HPV, PapilloTyper, HepB Typer-Adefovir, and HepB Typer-Precore among others.

Genematrix Headlines

No Headlines